ArticleClinical rheumatology2026
Study on the chemokine CXCL10 in serum for its value in GCA-PMR spectrum disease stratification.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Serum protein biomarkers for polymyalgia rheumatica: a case-control study.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo investigate the value of chemokine CXCL10 in clinical stratification across the spectrum of diseases encompassing giant cell arteritis (GCA) and polymyalgia rheumatica (PMR).
methodsA total of eight newly diagnosed GCA patients (active GCA group), nine treated and remitted GCA patients (remission GCA group), 40 newly diagnosed PMR patients (active PMR group), 37 PMR patients in remission, and 31 healthy individuals undergoing physical examinations (healthy control group) were selected. Serum CXCL10 levels were measured using ELISA. Statistical analysis was performed to evaluate the role of CXCL10 in differential diagnosis and clinical stratification within the GCA-PMR spectrum disease.
resultsSerum CXCL10 levels in the active GCA group were significantly higher than in the healthy control group (Z = - 3.826, P < 0.001) and the active PMR group (Z = - 3.071, P = 0.001). Serum CXCL10 levels in the GCA remission group were significantly higher than in the healthy control group (Z = - 3.806, P < 0.001) and the PMR remission group (Z = - 3.918, P < 0.001). The ROC curve analysis indicates that CXCL10 is valuable for differential diagnosis between active GCA and PMR (AUC = 0.847, sensitivity = 0.7, specificity = 1, cut-off value = 51.87), as well as between remission-phase GCA and PMR (AUC = 0.925, sensitivity = 0.838, specificity = 1, cut-off value = 45.17).
conclusionThe chemokine CXCL10 may be involved in the pathogenesis of GCA and helps distinguish between clinical stratification of GCA and PMR within GPSD. Key Points • The concentrations of CXCL10 was higher in peripheral blood of GCA patients. • The level of CXCL10 might contribute to the stratification of GCA-PMR spectrum disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.